Contemporary Management of HIV-HCV Coinfection
|
|
- Florence Reeves
- 6 years ago
- Views:
Transcription
1 Contemporary Management of HIV-HCV Coinfection Elizabeth Sherman, PharmD, AAHIVP Faculty, South Florida - Southeast AIDS Education & Training Center HIV/AIDS Clinical Pharmacist, Memorial Healthcare System Assistant Professor, Nova Southeastern University esherman@nova.edu
2 Disclosures The activity planners and speakers do not have any financial relationships with commercial entities to disclose. The speakers will not discuss any off-label use or investigational product during the program. This slide set has been peer-reviewed to ensure that there are no conflicts of interest represented in the presentation
3 Learning Objectives Apply current guidelines on hepatitis C virus (HCV) screening Manage patients with HCV infection while recognizing adverse effects and drug interactions Counsel patients regarding current HCV treatment options, timing of treatment, and key characteristics of current regimens
4 Introduction
5 Chronic Hepatitis C Virus (HCV) Is a Progressive Disease HEALTHY LIVER FIBROTIC LIVER CIRRHOTIC LIVER Chronic HCV frequently has few or no symptoms and can progress without signs for decades [1] Most patients with chronic HCV are asymptomatic until serious liver complications arise [2] 1. CDC. MMWR Morb Mortal Wkly Rep. 1998;47(RR-19): Heidelbaugh JJ, et al. Am Fam Physician. 2006;74:
6 HCV in the US: Gaps in Current Practice % 80 Pts (%) % 43% 27% 20 17% 16% 9% 0 Chronic HCV Infected Diagnosed and Aware Access to Outpatient Care HCV RNA Confirmed Underwent Liver Biopsy Prescribed HCV Treatment Achieved Sustained Viral Response n = 3,500,000 1,743,000 1,514, , , , ,859 Yehia BR, et al. PLoS One. 2014;9:e
7 Current All-Oral Therapies Highly Effective, Simple, Well Tolerated Standard Interferon (IFN) 1991 Ribavirin (RBV) Peginterferon (pegifn) Direct-Acting Antivirals (DAAs) All-Oral Therapy Current IFN 6 Mos IFN 12 Mos IFN/RBV 6 Mos IFN/RBV 12 Mos PegIFN 12 Mos PegIFN/RBV 12 Mos PegIFN/ RBV + DAA DAA + RBV ± PegIFN All Oral DAA± RBV
8 Case 1: When and How to Screen for Hepatitis
9 Case 1: 56-Yr-Old Woman Presenting to Primary Care A 56-yr-old woman visits your office She has recently moved to the area following a promotion and is looking for a primary care clinician She is not aware of having been tested for HCV infection previously
10 CDC, USPSTF, and AASLD/IDSA HCV Screening Recommendations Population Recommendation Age One-time screening is recommended for persons born between 1945 and 1965, without ascertainment of HCV risk [1-3] Risk One-time screening is recommended for persons with these risk factors [1,3] : History of illicit injection drug use (IDU) or intranasal illicit drug use History of long-term hemodialysis Receiving a tattoo in an unregulated facility/setting Healthcare workers upon accidental exposure Children born to anti-hcv positive mothers History of transfusion with blood or organ transplantation Were ever in prison HIV infection Chronic liver disease/hepatitis with unknown cause, including elevated liver enzymes Annual screening is recommended for current IDUs and HIV-infected MSM [3] 1. Smith BD, et al. MMWR Recomm Rep. 2012;61(RR-4): US Preventive Services Task Force. HCV Screening Guidelines AASLD-IDSA. HCV Guidelines 2017.
11 Hepatitis C Prevalence is Increased in Baby Boomers Prevalence of Hepatitis C Antibody Positivity in US Population by Sex by Yr of Birth (NHANES III) 10 Prevalence of Hepatitis C Positive (%) Screening recommended Male Female Yr of Birth Iwasaki K, et al. ISPOR Abstract PG17.
12 Talking to Patients About Hepatitis C Testing Provide rationale for testing Provide reassurance about testing Obtain consent
13 Talking to Patients About Hepatitis C Testing Provide rationale for testing It s common Provide reassurance about testing It s curable Obtain consent If it s alright with you, I would like to test you for hepatitis C today
14 Back to Our Case A 56-yr-old woman visits your office She has recently moved to the area following a promotion and is looking for a primary care clinician Routine hepatitis C antibody test: reactive
15 Recommended Testing Sequence for Identifying Current HCV Infection HCV antibody test Reactive HCV RNA test Detected Current HCV infection Provide care or link to care Nonreactive Stop Not detected No current HCV infection Additional testing as appropriate CDC. MMWR Morb Mortal Wkly Rep. 2013;62:
16 Recommendations for Additional Follow-up of Initial HCV Testing Quantitative hepatitis C RNA testing prior to initiation of antiviral therapy to document baseline viral load Testing for hepatitis C genotype all genotypes can be treated, but genotype will guide choice of antiviral therapy AASLD-IDSA. HCV Guidelines 2017.
17 Counseling for HCV-Infected Individuals Prevent HCV Transmission Avoid sharing toothbrushes, dental, shaving equipment Prevent blood contact; do not donate blood Avoid illicit drugs; avoid reusing or sharing drug paraphernalia Risk of sexual transmission is low, except for people with HIV, multiple partners, or STIs Reduce Progression of Liver Disease Test for conditions that accelerate fibrosis (Hepatitis B and HIV) Evaluate for advanced fibrosis Update vaccinations Avoid alcohol
18 Recommendations for When and in Whom to Initiate HCV Treatment Treatment is recommended for all pts with chronic hepatitis C infection, regardless of genotype Except where life expectancy likely to be short despite treatment or transplantation AASLD-IDSA. HCV Guidelines 2017.
19 All-Cause Mortality (%) HCV Virologic Cure Associated with Improved Outcomes P <.001 All-Cause Mortality Without SVR With SVR Yr HR: 0.26 (95% CI: ; P <.001) Liver-Related Mortality or Liver Transplantation (%) Liver-Related Mortality or Liver Transplantation P <.001 Without SVR With SVR Virologic cure does not protect against reinfection van der Meer AJ, et al. JAMA. 2012;308: Yr
20 Fibrosis Staging Determines treatment (e.g., use of ribavirin) and treatment duration Metavir Stage 0-2: No fibrosis or portal fibrosis Metavir Stage 3-4: Advanced fibrosis or cirrhosis Noninvasive strategies: APRI (AST platelet ratio index), FIB-4, FibroSure, FibroScan
21 Case 2 Ongoing Management of HCV
22 Case 2: 45-Yr-Old Man With Hepatitis C Infection A 45-yr-old man visits your office Diagnosed with chronic HCV in 2011, previously treated with peginterferon and ribavirin Noninvasive markers suggest Metavir stage 2 (some fibrosis) Now expresses interest in hepatitis C therapy after hearing positive reports about new oral treatments
23 Case 2: Initial Workup Parameter Coinfections HCV genotype HCV RNA FibroSure Finding HAV negative, HBV negative, HIV negative 1a 3,500,000 IU/mL F2 Parameter Finding WBC 3500 cells/mm 3 Hemoglobin 14 g/dl Platelets 155/μL INR 1.0 Albumin 3.8 mg/dl Total bilirubin 1.2 mg/dl AST 68 IU/mL ALT 64 IU/mL Alk phos 155 IU/mL Creatinine 1.2 mg/dl
24 Many Options in 2017: Current All-Oral Regimens for Hepatitis C Infection Regimen Approved Genotypes Grazoprevir/elbasvir 1, 4 Ombitasvir/paritaprevir/rit onavir Ombitasvir/paritaprevir/rit onavir + dasabuvir Sofosbuvir + daclatasvir 1, 3 Sofosbuvir/ledipasvir 1, 4, 5, 6 Simeprevir + sofosbuvir 1, 4 Sofosbuvir/velpatasvir 1, 2, 3, 4, 5, 6 Sofosbuvir/velpatasvir/vo xilaprevir 4 1 1, 2, 3, 4, 5, 6 Effective options for every genotype Single-pill formulations or 2-pill combinations Effective for all genotypes
25 HCV Drug Targets: Helpful Hints -previr NS3 protease inhibitors -buvir NS5B inhibitors -asvir NS5A inhibitors
26 HCV Treatment: Get to Know Your Patient HCV genotype? Presence of cirrhosis? Previous HCV therapy? Helps tailor: Treatment options Treatment duration Need for ribavirin Key Resource:
27 Adverse Events and Drug-Drug Interactions
28 Adverse Events Newer hepatitis C medications do not have same adverse events as interferon and are generally well tolerated Discuss most common adverse events and management strategies in pre-education session Headaches: nonpharmacologic management strategies, limits of OTC pain relievers and liver disease Anemia: still a concern when ribavirin needed Encourage patients to report bothersome or unusual adverse events
29 Ribavrin Considerations Most patients won t need it! If they do Discuss contraception Check baseline hemoglobin and test for anemia through treatment Counsel on anemia symptoms Know that anemia can be managed for most while completing HCV therapy
30 Pretreatment: Look for Potential Drug Drug Interactions Review all herbals/supplements, prescription and OTC meds, including contraceptives and proton pump inhibitors Ask about PRN usage of other drugs Consult with clinical pharmacist when possible Key Resource:
31 Drug Interactions in the HIV-HCV Coinfected Patient Priority population for treatment SVR rates similar to HCV monoinfected [1,2] In HCV/HIV coinfection, treat HCV as though HCV monoinfected, but consider drug drug interactions [3] Drug drug interactions may require careful selection of HCV regimen or changes in HIV ART regimens Non-HIV providers require collaboration with the patient s HIV provider 1. Naggie S, et al. N Engl J Med. 2015;373: Wyles DL, et al. N Engl J Med. 2015;373: AASLD/IDSA Guidelines. February 2016.
32 SIM + SOF HCV Interactions With ART LDV/ SOF SOF + DCV PTV/RTV/ OBV + DSV PTV/RTV/ OBV EBV/ GZR SOF/ VEL SOF/VEL/ VOX Atazanavir + RTV or COBI Χ Χ Χ Χ Darunavir + RTV or COBI Χ Χ Χ Raltegravir Dolutegravir Elvitegravir/ COBI/FTC/ TDF Χ Χ Χ Χ Χ Elvitegravir/ COBI/ FTC/ TAF Χ Χ* Χ Χ Efavirenz Χ Χ Χ Χ Χ Χ Rilpivirine Χ Χ Abacavir/ lamivudine Emtricitabine/ TDF Emtricitabine/ TAF No clinically significant interaction expected nephrotoxicity nephrotoxicity nephrotoxicity Potential interaction may require adjustment to dosage, timing of administration, or monitoring Χ Do not coadminister
33 Other Selected Potential Drug Drug Interactions with HCV Agents Concomitant Medication SIM/ SOF LDV/ SOF SOF/ DCV PTV/RTV/ OBV + DSV PTV/RTV/ OBV EBV/ GZR SOF/ VEL SOF/ VEL/VOX Acid-reducing agents* X X X X X Amiodarone X X X X X X X Anticonvulsants X X X X X X X X Digoxin X X X X X X Ethinyl estradiol containing products Glucocorticoids X X X X X PDE5 inhibitors X X X X Rifamycin antimicrobials X X X X X X X X St John s wort X X X X X X X X Statins X X X X X X X X X X *eg, proton pump inhibitors such as omeprazole. Including inhaled, intranasal. AASLD/IDSA Guidelines
34 Supporting Patients During Antiviral Therapy Recommendations Offer clinic visits or telephone contact to ensure adherence and to monitor for adverse events and drug interactions CBC, creatinine level, egfr, hepatic function panel at week 4 and as clinically indicated Quantitative HCV RNA at week 4 of treatment and again at 12 wks after completion of treatment (SVR) AASLD-IDSA. HCV Guidelines Key Resource:
35 Post-Treatment Follow-up
36 Characteristic Recommended Follow-up After Hepatitis C Treatment Follow-up No advanced fibrosis (Metavir stage F0-F2) No hepatitis C follow-up Advanced fibrosis (Metavir stage F3 or F4) Twice-yearly ultrasound surveillance for hepatocellular carcinoma If compensated cirrhosis (F4) also test for varices using baseline endoscopy Ongoing hepatitis C risk or unexplained hepatic dysfunction Test for recurrence or reinfection with quantitative hepatitis C RNA assay Persistently abnormal liver tests Test for other causes of liver disease No virologic cure Test for disease progression every 6-12 months with hepatic function panel, CBC, and INR Consider retreatment options
37 Summary Patients born should be screened for HCV infection Know risk-based screening recommendations Virtually all with HCV infection should be treated, regardless of genotype and fibrosis Prevents morbidity, progression of fibrosis, hepatocellular carcinoma Current treatments include pangenotypic and ribavirin-free options > 95% rate of cure for most genotypes Most therapies are 12 wks, ribavirin free, all oral, once daily Many patients can be treated in primary care setting Counsel and monitor for adverse effects and drug interactions
38 This Presentation and resources are made possible by AETC grant award U1OHA29295 from the HIV/AIDS Bureau of the Health Resources Services Administration (HRSA), U. S. Department of Health and Human Services (HHS). The information presented is the consensus of HIV/AIDS specialists within the SEAETC and does not necessarily represent the official views of HRSA/HAB The AIDS Education and Training Center (AETC) Program is the training arm of the Ryan White HIV/AIDS Program. The AETC Program is a national network of leading HIV experts who provide locally based, tailored education, clinical consultation and technical assistance to healthcare professionals and healthcare organizations to integrate high quality, comprehensive care for those living with or affected by HIV.
39
Updates in the Treatment of Hepatitis C
Disclosures Updates in the Treatment of Hepatitis C Arslan Kahloon M.D Assistant Professor of Medicine University of Tennessee, Chattanooga I have no conflicts of interest or financial sponsorship to disclose
More informationHepatitis C Update: A Growing Challenge With Evolving Management Solutions
Pts (%) Hepatitis C Update: A Growing Challenge With Evolving Management Solutions A Growing Challenge With Evolving Management Solutions Introduction Magda Houlberg, MD Chief Clinical Officer Howard Brown
More informationHepatitis C Update on New Treatments
Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationOutline. HCV Disease Outcomes in the US. Hepatitis C: The New Landscape 5/24/16. Advances in Internal Medicine May 24, I have no disclosures
5/24/16 Hepatitis C: The New Landscape Advances in Internal Medicine May 24, 2016 I have no disclosures Rena K. Fo, MD Professor of Clinical Medicine, UCSF Outline I. Current HCV outcomes in the US II.
More informationEpidemiology and Screening for Hepatitis C Infection
Epidemiology and Screening for Hepatitis C Infection Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Epidemiology/Screening for Hepatitis
More informationHepatitis C ew Medications, New Hope and New. V. Opportunities for Primary Care. Outline. HCV Disease Outcomes in the US 9/21/2016
Hepatitis C ew Medications, New Hope and New Opportunities for Primary Care Primary Care Principles and Practice October 14, 2016 Disclosures: Grant support Gilead Sciences, Inc Quality improvement Systematized
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationTreating Chronic HCV with Direct-Acting Antivirals (DAAs)
Treating Chronic HCV with Direct-Acting Antivirals (DAAs) Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org/hcv-infection Purpose of the HCV Guideline
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationBrief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV)
Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV) James Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital www.mghcme.org Disclosures Neither
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationHepatitis C: the 2015 Perspective for the Family Medicine Practitioner
Hepatitis C: the 2015 Perspective for the Family Medicine Practitioner Annie Luetkemeyer, MD Division of HIV,ID & Global Medicine San Francisco General Hospital Disclosures I have received research grant
More informationHIV and Hepatitis C Have we finally slayed the beast?
HIV and Hepatitis C Have we finally slayed the beast? Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Accelerated Fibrosis in HIV-HCV co-infected
More informationDisclosures. Outline Update on HCV management & treatment in Primary care. What role does the Family Practice Provider play in HCV care in 2014?
Disclosures 2014 Update on HCV management & treatment in Primary care Annie Luetkemeyer HIV Division San Francisco General Hospital I have received research grant support to UCSF related to HCV from the
More informationCARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS
CARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND APRIL 26, 2018 CME Disclosures: Planning Committee And Speaker Speaker: The following speaker has
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationHepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?
Hepatitis C Jennifer Acosta PA-C No disclosures 1. The USPSTF recommends Hepatitis C screening in which patient populations? a. All adults at least once b. Immigrants to the US and those over age 65 c.
More informationProgram Disclosure. A maximum of 1.5 contact hours may be earned for successful completion of this activity.
Program Disclosure This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationManaging New Treatments for Hepatitis C in Primary Care
Managing New Treatments for Hepatitis C in Primary Care Christina Connel, PharmD, BCPS, AAHIVP Objectives 2 Review HCV disease burden Identify risk factors and recommended testing for HCV Describe who
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationHepatitis C Genotype 1 (GT 1) Patients in the United States (US)
Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or
More informationHepatitis C in the HIV Co-infected Population: Where are we today?
Hepatitis C in the HIV Co-infected Population: Where are we today? Sherilyn Brinkley MSN, CRNP Viral Hepatitis Center John G. Bartlett Specialty Practice 1 Disclosures Consulting and fees for non-cme/ce
More informationHCV Disease Outcomes in the US. Hepatitis C New Medications, New Hope and New Opportunities for Primary Care. Learning Objectives 10/13/17
Hepatitis C New Medications, New Hope and New Opportunities for Primary Care Disclosures: Grant for quality improvement Gilead In this talk, 10 drugs will be discussed, 4 of which are manufactured by Gilead.
More informationDisclosures. Lisa M. Chirch, MD, FIDSA has disclosed that she has served on advisory boards for Gilead Sciences and Melinta Therapeutics.
HEPATITIS C IN 2017 Lisa M. Chirch, M.D. Associate Professor of Medicine University of Connecticut Health Center A Local Performance Site of the New England AETC Disclosures Lisa M. Chirch, MD, FIDSA has
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationHIV INFECTION AND HEPATITIS C LUIS A. ESPINOZA, MD
HIV INFECTION AND HEPATITIS C LUIS A. ESPINOZA, MD Financial Disclosure None (Updated March 8, 2016) 2 Learning Objectives 1. Discuss the epidemiology of hepatitis C and populations at risk for hepatitis
More informationGlobal Prevalence of HBV, HCV, HIV
Treatment of Patients with HCV and HIV Paul Y. Kwo, MD, FACG Professor of Medicine Stanford University email: pkwo@stanford.edu Global Prevalence of HBV, HCV, HIV 24 m Journal of Clinical Virology Page
More informationHepatitis C Virus Management
Hepatitis C Virus Management FORMATTED: 04/20/17 New York, New York: February 24, 2017 Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine University of California San Francisco San
More informationMy HCV patient is co-infected with HIV: how to manage?
EASL «White Nights of Hepatology 2016» My HCV patient is co-infected with HIV: how to manage? A.V. Кravchenko MD, Professor Russia AIDS Federal Center Central Research Institute of Epidemiology St.-Petersburg,
More informationP4C HIV TAC Collaborative Training: Hepatitis C Virus (HCV) Treatment Guidelines
P4C HIV TAC Collaborative Training: Hepatitis C Virus (HCV) Treatment Guidelines Presenter: Stacey B. Trooskin, M.D., Ph.D Director of Viral Hepatitis Programs Philadelphia FIGHT Community Health Centers
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationNew Hepatitis C Antivirals
New Hepatitis C Antivirals Kris Stewart, BSP, MD, FRCPC Drug Therapy Conference College of Medicine, University of Saskatchewan September 23, 2016 Disclosures I have received research and program support
More informationWorld Health Organization. Western Pacific Region
Advanced modules for HCV 1 HCV Module 1 Hepatitis C serological markers and virology 2 HCV Markers 3 Test Anti HCV (Anti hepatitis C virus antibody) HCV RNA (quantitative or qualitative) (Nucleic acid
More informationMEDICATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C
MEDICATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C Annette Hewitt, ARNP, Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium CONFLICT OF INTEREST DISCLOSURE STATEMENT None. I will
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationDisclosures. Hepatitis C: the 2016 Perspective. The Take Home. Glossary 12/9/16
Disclosures Hepatitis C: the 2016 Perspective Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF I have received research grant support to UCSF related to HCV from the following:
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationHepatitis C: Newest Treatment Options and What To Do When We Cure It!
Hepatitis C: Newest Treatment Options and What To Do When We Cure It! Richard Kalman, MD Division of Hepatology Department of Transplantation Einstein Medical Center Learning Objectives Scope of HCV How
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationYour Annual Hepatitis C Update
Your Annual Hepatitis C Update Bernadette Jakeman, Pharm.D. Associate Professor University of New Mexico, College of Pharmacy Nimish Patel, Pharm.D., Ph.D. Associate Professor University of California
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate
More informationTreating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World H. Nina Kim, MD MSc Associate Professor of Medicine University of Washington Division of Allergy & Infectious Diseases April 21, 2017
More informationLength of Authorization: 8-12 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationCases: Initial Treatment of Hepatitis C
Cases: Initial Treatment of Hepatitis C Kristen Marks, MD Assistant Professor of Medicine Weill Cornell Medical College New York, New York Off-Label Warning I will discuss the following off-label use in
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationDisclosure. HCV Update & Case-Based Scenarios in Hepatitis C HCV AT THE CUTTING EDGE. Kristen Marks, MD Weill Cornell Medical College New York, NY
HCV Update & Case-Based Scenarios in Hepatitis C HCV AT THE CUTTING EDGE Kristen Marks, MD Weill Cornell Medical College New York, NY Final Disclosure Dr Marks has received grants and research support
More informationChronic Hepatitis C: An Update on Screening, Evaluation, and Management
Chronic Hepatitis C: An Update on Screening, Evaluation, and Management Donald Gardenier, DNP, FNP-BC, FAANP, FAAN Assistant Professor and Clinical Program Director Icahn School of Medicine at Mount Sinai
More informationHIV/hepatitis co-infection. Christoph Boesecke Department of Medicine I University Hospital Bonn Germany
HIV/hepatitis co-infection Christoph Boesecke Department of Medicine I University Hospital Bonn Germany Clinical Management and Treatment of HBV and HCV Co-infection in HIVpositive Persons Hepatitis B
More informationTreating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
More informationREQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments
Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber
More informationGUIDELINES FOR INCORPORATING HIV/HCV PREVENTION INTO MEDICAL CARE
GUIDELINES FOR INCORPORATING HIV/HCV PREVENTION INTO MEDICAL CARE JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND JANUARY 25, 2018 CME Disclosures: Planning Committee And Speaker Speaker: The following
More informationChronic viral hepatitis and liver disease in Belgium Pierre Deltenre
Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationHCV Screening, Management, and Treatment Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management, and Treatment Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationHepatitis C Virus: HIV/Hepatitis C Coinfection Wednesday, August 24, 2016
Hepatitis C Virus: HIV/Hepatitis C Coinfection Debika Bhattacharya, MD, MSc Associate Clinical Professor University of California Los Angeles Los Angeles, California Washington, DC: August 24, 2016 Slide
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationMolina Healthcare of Texas Hepatitis C Drugs (Medicaid)
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review
More informationCase 1: Chronic Hepatitis C
Case 1: Chronic Hepatitis C Moderator Dawn Pease, MSN, RN, ANP-BC Seton Healthcare Family University Medical Center Brackenridge Brackenridge Specialty Clinics - Gastroenterology and Endocrinology Austin,
More informationHepatitis C Screening, Prevention, and Treatment: Lo que aprendimos trabajando con comunidades Latinas
Hepatitis C Screening, Prevention, and Treatment: Lo que aprendimos trabajando con comunidades Latinas Center for Research to Advance Community Health (ReACH) University of Texas Health Science Center
More information